摘要
目的评价黑升麻异丙醇提取物(莉芙敏)治疗围绝经期综合征的安全性和疗效。方法 98例符合入选标准的患者随机分成观察组和对照组,各49例,均治疗12周。比较两组的KMI评分、阴道萎缩症状评分和不良事件发生率。结果观察组在改善KMI评分和阴道萎缩症状评分方面与对照组相当,差异无统计学意义(P>0.05);但其子宫内膜增厚、乳腺胀痛和阴道流血等不良事件发生率显著低于对照组,差异有统计学意义(P<0.05)。两组性激素、糖脂代谢和肝肾功指标变化比较差异无统计学意义(P>0.05)。结论莉芙敏治疗围绝经期综合征安全性高、效果好。
Objective To compare the efficacy and safety of Remifemin in the treatment of Perimenopause syndrome. Methods According to inclusion and exclusion criteria,a total of 98 patients were randomly allocated to receive either Remifemin （40 mg/day） or Tibolon （2. 5 rag/day） for 12 weeks. The Kupperman＇s score, vaginal atrophy＇s score, and adverse events were compared before and after treatment. Results There was no significant difference between two groups in Kupperman＇s scores and vaginal atrophy＇s score （P〈0.05）. Remifemin showed less side effects compared with Tibolon （P 〈 0. 05）. Conclusion Remifemin is effective and safe in relief of perimenopause syndrome.
出处
《成都医学院学报》
CAS
2015年第2期229-232,共4页
Journal of Chengdu Medical College
